AbbVie’s Aquipta secures MHRA marketing nod to prevent migraines
The authorisation was based on the findings from two Phase 3 trials in which the treatment met their…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
05 Sep 23
The authorisation was based on the findings from two Phase 3 trials in which the treatment met their…
05 Sep 23
Orion Health's DFD is designed to help people in their healthcare journey whilst supporting health systems' existing constraints…
05 Sep 23
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products,…
05 Sep 23
This is a strategic acquisition for Cipla South Africa to unlock the future growth opportunities and leverage cost…
05 Sep 23
Important ideas for the entire health market
05 Sep 23
This agreement follows Nestlé's announcement last year that it would conduct a strategic review of Palforzia
04 Sep 23
The consent order agreement with FTC allows Amgen to complete its proposed $27.8bn acquisition of Horizon Therapeutics, while…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
04 Sep 23
The sJNDA is based on the data from the Phase 3 MERIT trial that examined the efficacy and…
04 Sep 23
The approval was based on the findings from the ASCEND global Phase 3 trial and a Phase 1/2…
04 Sep 23
Letybo is a product in the Korean botulinum toxin market that has successfully entered global markets like China,…